| Popis: |
Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the secondor third-line setting. Methods: In this retrospective and multicenter study, advanced HCC patients not eligible for local therapies, who received a secondor third-line regorafenib therapy after progression on the first-line sorafenib or sequential therapy with chemotherapy (CT) followed by sorafenib, were included. Results: In the first-line setting, 28 (28.9%) patients received CT and 69 (71.1%) patients received sorafenib. There were 24 (24.7%) patients who were intolerant to sorafenib. Disease control rate (DCR) was 53.6% for all patients treated with regorafenib, 62.3% in patients who received regorafenib in the second-line, and 32.1% for those receiving regorafenib in the third-line (p=0.007). Median progression-free survival (PFS) and overall survival (OS) were 5.6 (range; 4.3-6.9) and 8.8 (range, 6.3-11.3) months for all patients treated with regorafenib vs. 7.1 months and 10.3 months for patients who received regorafenib in the second-line vs. 5.1 and 8.7 months for patients who received regorafenib in the third-line, respectively; however, there was no statistically significant difference (p(PFS)=0.22 and p(OS)=0.85). Conclusion: Although receiving CT as a first-line therapy in advanced HCC patients did not affect the survival rates of subsequent regorafenib therapy, it might diminish the DCR of regorafenib. C1 [Hacioglu, Muhammet Bekir; Kostek, Osman; Erdogan, Bulent; Cicin, Irfan] Trakya Univ, Dept Med Oncol, Med Fac, Edirne, Turkey. [Karabulut, Senem; Tastekin, Didem] Istanbul Univ, Med Fac, Dept Med Oncol, Istanbul, Turkey. [Goksu, Sema Sezgin] Akdeniz Univ, Med Fac, Dept Med Oncol, Antalya, Turkey. [Alandag, Celal] Karadeniz Tech Univ, Med Fac, Dept Med Oncol, Trabzon, Turkey. [Akagunduz, Baran] Dokuz Eylul Univ, Med Fac, Dept Med Oncol, Izmir, Turkey. [Bilgetekin, Irem] Dr Abdurrahman Yurtaslan Ankara Oncol Training &, Dept Med Oncol, Ankara, Turkey. [Caner, Burcu; Sahin, Ahmet Bilgehan] Uludag Univ, Med Fac, Dept Med Oncol, Bursa, Turkey. [Yildiz, Birol] Gulhane Training & Res Hosp, Dept Med Oncol, Ankara, Turkey. [Kose, Fatih] Baskent Univ, Adana Med Fac, Dept Med Oncol, Adana, Turkey. [Kaplan, Muhammet Ali] Dicle Univ, Med Fac, Dept Med Oncol, Diyarbakir, Turkey. [Gulmez, Ahmet] Inonu Univ, Med Fac, Dept Med Oncol, Malatya, Turkey. [Dogan, Ender] Erciyes Univ, Med Fac, Dept Med Oncol, Kayseri, Turkey. [Kilickap, Saadettin] Hacettepe Univ, Med Fac, Dept Med Oncol, Ankara, Turkey. [Guven, Deniz Can; Gurbuz, Mustafa] Ankara Univ, Med Fac, Dept Med Oncol, Ankara, Turkey. [Ergun, Yakup] Ankara Numune Training & Res Hosp, Dept Med Oncol, Ankara, Turkey. [Karaagac, Mustafa] Necmettin Erbakan Univ, Med Fac, Dept Med Oncol, Konya, Turkey. [Demiray, Atike Gokcen] Pamukkale Univ, Med Fac, Dept Med Oncol, Denizli, Turkey. [Turker, Sema] DiskapiYildir Beyazit Training & Res Hosp, Dept Med Oncol, Ankara, Turkey. [Sakalar, Teoman] Sakarya Univ Training & Res Hosp, Dept Med Oncol, Aksaray, Turkey. [Ozkul, Ozlem] Sakarya Univ Training & Res Hosp, Dept Med Oncol, Sakarya, Turkey. [Telli, Tugba Akin] Marmara Univ, Med Fac, Dept Med Oncol, Istanbul, Turkey. [Sahin, Suleyman] Van Training & Res Hosp, Dept Med Oncol, Van, Turkey. [Bilici, Ahmet] Medipol Univ, Med Fac, Dept Med Oncol, Istanbul, Turkey. |
